ISPE is excited to present the ICPE All Access Special COVID-19 Sessions. These 60-minute sessions will feature four presentations of 10 minutes in length with a Q&A period in the end.<\/p>\n\n\n\n
These sessions are complimentary, you do not have to be registered for ICPE All Access to attend!<\/p>\n\n\n\n
International collaboration on real-world evidence in COVID-19<\/strong> Since the declaration of COVID-19 as a pandemic there has been an explosion of real-world evidence (RWE) publications. Many of these publications have been based on small populations, methodological vigour has not always been optimal and the quality of reporting, including results being made public prior to peer-review, has often made interpreting the results difficult. International regulatory collaboration on RWE studies about COVID-19 has the potential to increase the size of populations being studied and to increase methodological vigour and quality of reporting through the sharing of expertise.<\/p>\n\n\n\n Register HERE<\/a><\/p>\n\n\n\n <\/p>\n\n\n\n Description of COVID-19 patients\u2019 characteristics<\/strong> Register HERE<\/a><\/p>\n\n\n\n <\/p>\n\n\n\n Outcomes in patients with COVID-19<\/strong> Register HERE<\/a><\/p>\n\n\n\n Race, gender, disparities, social isolation, and social distancing of\u00a0COVID-19<\/strong> Register HERE<\/a><\/p>\n\n\n\n Specific Treatment-outcome association studies of COVID-19<\/strong> Register HERE<\/a><\/p>\n\n\n\n Algorithm, model, methods of COVID-19<\/strong> Register HERE<\/a><\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" ISPE is excited to present the ICPE All Access Special COVID-19 Sessions. These 60-minute sessions will feature four presentations of 10 minutes in length with a Q&A period in the end. These sessions are complimentary, you do not have to be registered for ICPE All Access to attend! International collaboration on real-world evidence in COVID-19Date:\u00a0November … Continue reading “ICPE All Access Special COVID-19 Sessions”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[],"_links":{"self":[{"href":"https:\/\/canaim.ca\/wp-json\/wp\/v2\/posts\/2172"}],"collection":[{"href":"https:\/\/canaim.ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canaim.ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canaim.ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/canaim.ca\/wp-json\/wp\/v2\/comments?post=2172"}],"version-history":[{"count":0,"href":"https:\/\/canaim.ca\/wp-json\/wp\/v2\/posts\/2172\/revisions"}],"wp:attachment":[{"href":"https:\/\/canaim.ca\/wp-json\/wp\/v2\/media?parent=2172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canaim.ca\/wp-json\/wp\/v2\/categories?post=2172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canaim.ca\/wp-json\/wp\/v2\/tags?post=2172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Date:<\/strong>\u00a0November 24, 2020\u00a0
Time:<\/strong>\u00a09:00 \u2013 10:00 am EST\u00a0
Speaker:<\/strong>\u00a0Dr. Peter Arlett, European Medicines Agency<\/p>\n\n\n\n
Date:<\/strong>\u00a0October 29, 2020\u00a0
Time:<\/strong>\u00a09:00 \u2013 10:00 am EST\u00a0
Moderator:\u00a0<\/strong>Stephen Schachterle<\/p>\n\n\n\n
Anton Potteg\u00e5rd, University of Southern Denmark, Odense, Denmark<\/em><\/li>
Mina Tadrous, Women’s College Hospital, Toronto, Canada<\/em><\/li>
Tarita Murray-Thomas, CPRD, MHRA, London, United Kingdom\u00a0<\/em><\/li>
Caihua Liang, Optum Epidemiology, Boston, USA<\/em><\/li><\/ul>\n\n\n\n
Date:<\/strong>\u00a0November 6, 2020\u00a0
Time:<\/strong>\u00a09:00 \u2013 10:00 am EST\u00a0
Moderators:\u00a0<\/strong>Ann McMahon and Montse Soriano-Gabarro<\/p>\n\n\n\n
Kathleen M. Andersen, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. Center for Drug Safety and Effectiveness, Baltimore, USA<\/em><\/li>
Hector S. Izurieta, US Food and Drug Administration, Silver Spring, USA<\/em><\/li>
Maria Kempner, Harvard Pilgrim Health Care Institute, Boston, USA, Harvard Medical School, Boston, USA<\/em><\/li>
Sierra Luciano, TriNetX, Inc., Cambridge, USA<\/em><\/li><\/ul>\n\n\n\n
Date:<\/strong>\u00a0November 30, 2020\u00a0
Time:<\/strong>\u00a09:00 \u2013 10:00 am EST\u00a0
Moderator:\u00a0<\/strong>TBD<\/p>\n\n\n\n
Alem Zekarias, Uppsala Monitoring Centre, Uppsala, Sweden<\/em><\/li>
Paul Coplan, Johnson and Johnson, New Brunswick, NJ, USA<\/em><\/li>
Amalia Issa, University of the Sciences in Philadelphia, Philadelphia, USA<\/em><\/li>
Ami Buikema, Optum, Eden Prairie, USA<\/em><\/li><\/ul>\n\n\n\n
Date:<\/strong>\u00a0December 1, 2020\u00a0
Time:<\/strong>\u00a09:00 \u2013 10:00 am EST\u00a0
Moderators:\u00a0<\/strong>Ann McMahon and Montse Soriano-Gabarro<\/p>\n\n\n\n
Ju Hwan Kim, Sungkyunkwan University, Suwon, Korea, Republic of<\/em><\/li>
Lars Christian Lund, University of Southern Denmark, Odense, Denmark<\/em><\/li>
Sascha Dublin, Kaiser Permanente Washington Health Research Institute, Seattle, USA, Department of Epidemiology, University of Washington, Seattle, USA\u00a0<\/em><\/li>
Anna Schultze, London School of Hygiene and Tropical Medicine, London, United Kingdom<\/em><\/li><\/ul>\n\n\n\n
Date:<\/strong>\u00a0December 3, 2020\u00a0
Time:<\/strong>\u00a09:00 \u2013 10:00 am EST\u00a0
Moderator:\u00a0<\/strong>Xiaojuan Li<\/p>\n\n\n\n
Miranda Davies, Drug Safety Research Unit, Southampton, United Kingdom<\/em><\/li>
Paul Coplan, Johnson and Johnson, New Brunswick, NJ, USA<\/em><\/li>
Sheryl Kluberg, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA<\/em><\/li>
Sonia Halhol, Evidera, Waltham, Canada<\/em><\/li><\/ul>\n\n\n\n